Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sanofi Pasteur Allies with SK Chemicals Co. of South Korea on PCV

Published: Friday, March 21, 2014
Last Updated: Thursday, March 20, 2014
Bookmark and Share
A long-term strategic business collaboration to co-develop and commercialize an innovative vaccine against pneumococcal infection to address global public-health needs.

Sanofi Pasteur has announced a long-term strategic cooperation with SK Chemicals Co. to co-develop an innovative pneumococcal conjugate vaccine (PCV).

This agreement will enable Sanofi Pasteur to access the global PCV market of $4 billion USD. The World Health Organization (WHO) recommends the use of PCVs in all countries.

The collaboration agreement includes research & development, production, and commercialization of a preventative pneumococcal disease vaccine. As part of the agreement, Sanofi will make an up-front payment of $23 million USD to SK Chemicals Co.

Both companies will co-invest in the development of the PCV vaccine project and, if successful, SK Chemicals would produce the innovative vaccine at its production facility located in An-dong--the southern part of Korea. The product, once registered, would be launched globally by Sanofi Pasteur with shared profits outside of Korea, where SK would commercialize it with exclusive rights.

“Sanofi Pasteur is committed to driving the open innovation strategy in improving global public-health concerns, and to this end, this collaboration with SK Chemicals will showcase a win-win partnership built on mutual strengths and expertise of each company” said Sanofi Pasteur CEO, Olivier Charmeil. “With this agreement, Sanofi Pasteur will enlarge its unique portfolio of products, embracing the value of open innovation.”

“This is an important milestone for SK and for Korea,” stated Mr. In-Serk Lee, CEO of SK Chemicals “We are proud to partner with Sanofi Pasteur, one of the global leaders of the vaccine industry, to be able to develop and manufacture in Korea a premium vaccine that has the potential to be distributed worldwide.”

According to the WHO, diseases caused by Streptococcus pneumoniae (pneumococcus)-such as pneumonia, meningitis and febrile bacteraemia-constitute a major, global public-health problem; otitis media, sinusitis and bronchitis are more common but less serious manifestations of infection. It is estimated that about 14.5 million episodes of serious pneumococcal disease occur annually, resulting in about 826,000 deaths in children aged 1-59 months.

SK Chemicals recently unveiled its quality by design, multi-product production facility. The plant is currently producing various vaccines for clinical trials. Once the testing is over, the plant will start producing vaccines at large scale using next-generation technologies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sanofi Pasteur and Immune Design Collaborate on a Vaccine to Treat HSV
The two companies will develop a product jointly through phase II.
Saturday, October 18, 2014
Sanofi Pasteur Initiates Phase III Study Investigational Clostridium Difficile Vaccine
Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide.
Wednesday, August 07, 2013
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Study Identifies How Brain Connects Memories Across Time
UCLA Neuroscientists have boost ability of aging brain to recapture links between related memories.
3-D Atomic Structure of Cholesterol Transporter
Researchers at UTSW have determined the 3-D atomic structure of a human sterol transporter that helps maintain cholesterol balance.
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Can We Break the Link Between Obesity and Diabetes?
Columbia University researchers identify a key molecule involved in the development of type 2 diabetes.
Fungi – A Promising Source Of Chemical Diversity
Moulds and plants share similar ways in alkaloid biosynthesis .
How Prions Kill Neurons: New Culture System Shows Early Toxicity to Dendritic Spines
Boston University researchers have developed a cell culture system to study prions.
Great Migration and African-American genomic diversity
Study examines genetic data to analyze regional differences in ancestry.
Faster, More Efficient CRISPR Editing
UC Berkeley scientists have developed a quicker and more efficient method to alter the genes of mice with CRISPR-Cas9, simplifying a procedure growing in popularity because of the ease of using the new gene-editing tool.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!